PR92181

FREIBURG, Germany, Oct. 12, 2021 /PRNewswire=KYODO JBN/ --

Eleva, a manufacturer of superior biologics, is entering clinical phases with

its own drug candidates, such as immune-regulating factor H, as well as in

collaboration with pharmaceutical partners. Its moss-based platform is ideally

suited to produce difficult-to-express but therapeutically promising drug

candidates.

Its recently expanded production capacity enables Eleva to conduct clinical

studies of its drug candidates. Among the first ones is factor H which will be

developed through phase II. Up to 2,500 l will be produced in state-of-the-art

single-use reactors at a GMP site.

Eleva's moss-based platform offers unique advantages for recombinant protein

development, such as:

- Moss glycostructure naturally lacks core á-1,6 fucose – a known allergen –

while any other glycans can be "humanized". This leads to excellent organ

uptake.

- Being a plant, it will not be contaminated with animal pathogens, which

eliminates the need for antibiotics.

- The moss production system, haploid by nature, is based on an intact

organism, not on cell cultures. This guarantees exceptionally stable

modifications.

Eleva is leveraging those advantages to produce complex proteins for future

therapies, such as 2nd generation oncological therapeutics, or

virus-like-particles (VLP) for vaccine development.

Ralf Smit, CBO of Eleva: "With production scaling up, we can now offer to

develop difficult-to-express therapeutic proteins in collaboration with

partners in the pharmaceutical industry. We look forward to our moss platform

unlocking the very promising potential of complex candidates for the benefit of

patients."

About Eleva

Based in Freiburg, Germany, Eleva develops novel biological therapies with its

pharmaceutical partners. The privately-held company leverages its unique

moss-based production platform to produce supreme biologics like antibodies,

replacement enzymes, or fusion toxins. Eleva has successfully developed drug

candidates into clinical phases.

Press contact

eleva GmbH

Fabienne Zeitter

pr@elevabiologics.com

Phone: +49 761 470 990

www.elevabiologics.com

Source: eleva GmbH